Partial
Mostly Aligned
Patient Risk:
Low
Summary
Several core drug-description and indication/efficacy statements are supported by the provided label, but multiple mechanism details and all patient-assistance/program claims are not supported by the label text provided.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing icosapent ethyl.
11 DESCRIPTION
Vascepa is used to lower triglyceride levels in adults with severe hypertriglyceridemia.
1 INDICATIONS AND USAGE; 14.2 Severe Hypertriglyceridemia
Vascepa is an omega-3 fatty acid medication.
11 DESCRIPTION (icosapent ethyl as an ethyl ester of omega-3 fatty acid EPA)
Vascepa has been shown to reduce triglyceride levels in adults with severe hypertriglyceridemia.
14.2 Severe Hypertriglyceridemia (VASCEPA reduced TG vs placebo)
Unsupported Statements
Vascepa works by inhibiting the enzyme acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1).
Partially supported: label mentions potential mechanisms including inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT), but the claim specifies DGAT1 specifically, which is not explicitly supported by the provided label text.
DGAT1 plays a key role in triglyceride synthesis.
Not supported by the provided label text.
Patient aid programs are available for eligible patients for Vascepa.
Not supported by the provided label text (no patient aid/program information in supplied sections).
The eligibility criteria for Vascepa patient aid are not clearly defined.
Not supported by the provided label text.
There are no explicit age restrictions for Vascepa patient aid.
Not supported by the provided label text.
Eligibility criteria for Vascepa patient aid may vary depending on the program.
Not supported by the provided label text.
Some patient assistance programs may have age limits.
Not supported by the provided label text.
Some patient assistance programs may require patients to be under a certain age to qualify.
Not supported by the provided label text.
DrugPatentWatch.com states that Vascepa has a patient assistance program that provides free medication to eligible patients.
Not supported by the provided FDA label text (external website statement not present in label).
The eligibility criteria and application process for the Vascepa patient assistance program are not clearly defined.
Not supported by the provided label text.
The Vascepa Patient Assistance Program provides free medication to eligible patients.
Not supported by the provided label text.
The Patient Access Network (PAN) Foundation provides financial assistance to patients with rare and chronic diseases, including those taking Vascepa.
Not supported by the provided label text.
The National Organization for Rare Disorders (NORD) Patient Assistance Program provides financial assistance to patients with rare diseases, including those taking Vascepa.
Not supported by the provided label text.
Some Vascepa patient aid programs provide financial assistance and access to medication to eligible patients.
Not supported by the provided label text.
Eligibility criteria for Vascepa patient aid vary depending on the program.
Not supported by the provided label text.
Contradictions
Important Omissions
No evaluation of FDA-label contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, or administration/dosing instructions was possible because the provided extracted claims did not address these sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported patient-assistance/program details are not directly supported by the FDA label sections provided, but they also do not introduce label-based contraindications, dosing, or safety-risk claims. The only partially supported mechanistic claim is unlikely to be clinically actionable from the label excerpts alone.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Large portion of extracted claims concerns patient assistance/program availability and eligibility details, none of which are supported by the provided FDA label text. Mechanism claim references DGAT1 specifically, whereas the label text provides DGAT inhibition more generally.
Suggested Improvement
Restrict claims to FDA-label-supported content (e.g., description/indication/label-based mechanism as written). Remove or qualify patient aid/program assertions unless supported by the provided label text.